Abstract
The purpose of the present study was to examine the relationship between the “tumor marker,” CA19-9, and benign biliary tract disease. We measured serum and bile CA19-9 in 40 patients with (1) symptomatic cholelithiasis (N=14), (2) common bile duct obstruction without cholangitis (N=8), (3) acute cholangitis secondary to gallstone disease (N=7), and (4) acute cholecystitis (N=11). All seven patients with acute cholangitis had marked elevations of serum CA19-9 (range 190-32,000 units/ml; 75 units/ml cutoff), whereas none of the patients in the other groups had elevated levels despite similar degrees of cholestasis and similarly high levels of CA19-9 in gallbladder and common duct bile (range 7.3×104−2.3×109 units/ml). Of the three patients with cholangitis in whom CA19-9 levels were followed serially, all had rapid return of levels to normal after successful treatment. We conclude that the “tumor marker” CA19-9 is markedly elevated in the serum of patients with acute cholangitis but not in patients with other forms of benign biliary tract disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ritts RE, DelVillano BC, Go VLM, Herberman RB, Klug TL, Zurawski VR: Initial clinical evaluation of an immunoradiometric assay for CA19-9 using NCI serum bank. Int J Cancer 33:339–345, 1984
Piantino P, Andriulli A, Gindro T, Pecchio F, Masoero G, Cavallini G, Naccarto R, Dobrilla G: CA19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am J Gastroenterol 81:436–439, 1986
Andriulli A, Gindro T, Piantino P, Farini R, Cavallini G, Piazzi L, Nacarrato R, Dobrilla G, Verme G, Sevro LA: Prospective evaluation of the diagnostic efficacy of CA19-9 assay as a marker for gastrointestinal cancers. Digestion 33:26–33, 1986
Tatsuta M, Yamamura H, Iishi H, Ichii M, Noguchi S, Yamamoto R, Okuda S: Values of CA19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 56:2669–2673, 1985
Malesci A, Tommasini MA, Bonato, Bocchia P, Bersani M, Zerbi A, Beretta E, diCarlo V: Determination of CA19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 92:60–67, 1987
Schmiegel WH, Kreiker C, Eberl W, Arndt R, Classen M, Greten H, Jessen K, Kalthoff H, Soehendra N, Thiele H-G: Monoclonal antibody defines CA19-9 in pancreatic juices and sera. Gut 26:456–460, 1985
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fulner P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5:957–972, 1979
Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, Toskes PP: Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 90:343–349, 1986
DelVillano BC, Brennan S, Brock P, Buchar C, Liu V, McClure M, Rake B, Space S, Westrick B, Shoemaker H, Zurawski VR: Radioimmunometric assay for a monoclonal antibody defined tumor marker CA19-9. Clin Chem 29:549–552, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Albert, M.B., Steinberg, W.M. & Henry, J.P. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Digest Dis Sci 33, 1223–1225 (1988). https://doi.org/10.1007/BF01536670
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01536670